This is Session 2 in the BioBusiness Insights: Opportunities in Regenerative Medicine series. Find out more about about all six sessions, and register for the series at a reduced rate below.
Funding, collaboration and partnering are integral to driving business success on a global platform. In this session, Dr Linda Somerville, Consultant, Contractor and Owner of Linfaws Consulting Limited (UK), will draw on her expertise in funding for collaborative and independent research, in line with her current contract with the UK Government’s Innovation Agency (Innovate UK).
Linda will provide an insight into the benefits for organisations looking to commercialise in the UK, exploring the opportunities and challenges that exist, and how R&D companies can best approach funding possibilities in the UK market.
Session 2 Details
Date: Tuesday 11 August 2020 Time: 4:30 pm – 5:30 pm AEST Format: This event will be delivered on a virtual platform – you will receive a link to join via a confirmation email following registration. Registration:
Single session: Members $35; Non-members $45
Complete series (six sessions)*: Members $150; Non-members $210
Unsure if your organisation is a member? Check our member directory.
*Please note: Session 1 has already taken place. New series registrations will be provided with a recording from this event.
Dr Linda Somerville, Consultant, Contractor and Owner, Linfaws Consulting Limited (UK)
Linda is an experienced cellular biologist; having worked in academia, industry and now as a contractor/consultant for the UK Government's Innovation Agency (Innovate UK). She has a strong technical background and has a passion for Research and Development, but ensures the research has commercial potential.
Having worked on both sides of the fence, Linda can understand the struggles researchers both in academia and industry face when funding is required. Linda ensures she provides support to the organisations she works with in the UK.
Linda has a PhD from Queen's University Belfast and over the course of her career is very well networked in the UK. Linda was recently invited to be a member of the Australian Regenerative Medicine Institute's Industry Advisory Committee.
Silvio Tiziani, CEO, CCRM Australia
Silvio Tiziani has played a key role in the establishment of Centre for Commercialisation of Regenerative Medicine (CCRM) Australia with the support of Canada’s CCRM, the Victorian Government and MTPConnect. Silvio is also Director, External Strategy and Planning at the Australian Regenerative Medicine Institute (ARMI). Silvio’s extensive knowledge of the research landscape is well utilised with his networks within the industry, international organisations and state and federal governments.
Silvio has extensive experience in private and public organisations, with a focus on laboratory-based services in government, private organisations, healthcare and research/academia.
In addition to qualifications that include a Bachelor of Science from Swinburne University and a Masters of Business Administration from Monash University, Silvio is also a graduate of the Australian Institute of Company Directors (GAICD). Silvio has extensive experience in financial analysis and budget management, business development, strategic planning and corporate governance along with strong interpersonal skills to lead staff.
Silvio also chairs the Ausbiotech Regenerative Medicine Advisory Group. Comprising leading representatives from industry and academia within the Australian regenerative medicine the Group provides specialist advice to Ausbiotech, Australia’s member-based biotechnology organisation, a peak body that promotes the global growth of Australian biotechnology.